Source: http://www.mondaq.com, September 11, 2019
By: Andrew N. Davis, Matthew Ranelli, Aaron D. Levy, Alfredo G. Fernández and Kristie A. Beahm, Shipman & Goodwin LLP
Any issue that poses the potential for health risks and/or liabilities associated with uncertain regulatory requirements demands corporate attention. Per- and polyfluoroalkyl substances (“PFAS”), a group of human-made chemicals, have flooded the news cycle, heightened regulatory attention and are ubiquitous. Whether or not a company knowingly made or used such materials, PFAS risk is an issue that requires C-Suite consideration. Read more.